3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
4
Pain, Postoperative
2
Neoplasms
2
Agnosia
2
Recurrence
1
Postoperative Cognitive Complications
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Myofibroma
1
Melanoma
1
Liver Neoplasms
1
Leiomyoma
1
Inflammatory Bowel Diseases
1
Diverticulitis
1
Delirium
1
Colonic Neoplasms
1
Cancer Surgery
1
Interventions
Sorafenib
61
Bevacizumab
42
Oxaliplatin
24
Doxorubicin
22
Radiosurgery
20
Gemcitabine
20
Fluorouracil
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
Capecitabine
17
lenvatinib
16
Cisplatin
16
atezolizumab
13
Leucovorin
13
Radiotherapy
11
tremelimumab
10
Cyclophosphamide
10
Carboplatin
10
Irinotecan
9
Ipilimumab
9
Drug Therapy
9
Everolimus
8
Cryosurgery
8
toripalimab
7
fludarabine
7
Sunitinib
7
Chemotherapy, Adjuvant
7
Melphalan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liver Neoplasms
×
Anesthesia, Spinal
×
Clear all
NCT03715517
2026-02-05
SAFER-L
University of Manitoba
Phase NA
Recruiting
128 enrolled